Valanx Biotech Secures €3 million in Latest Round of Financing

Valanx Biotech, a biotech company developing a technology for site-selectable, site-specific protein conjugation, has secured €3 million to advance its lead antibody-drug conjugate (ADC) program. The round of financing includes Foundation Fournier-Majoie and FUJIFILM Corporation as new investors, joining existing VC investors xista science ventures, tecnet equity, SOSV and angel investors Urs Spitz and SkyGene.

The financing will enable pre-clinical development of VLX-ADC-001, a LIV-1-targeting ADC for metastatic triple-negative breast cancer (mTNBC), with candidate selection planned for June 2026, while also supporting GMP readiness and partnering activities for the company’s GoldenSite conjugation platform.

Valanx’s GoldenSite platform is designed to enable rapid and reproducible, site-selectable conjugation. This allows development of ADCs and other conjugates with greatly improved therapeutic windows, addressing a key challenge in ADC development.

Michael Lukesch, Founder and Chief Executive Officer at Valanx Biotech, said: “LIV-1 is a compelling target in mTNBC, and GoldenSite gives us a practical way to precisely tune conjugation position to optimize the drug candidates therapeutic window. This close enables us to advance VLX-ADC-001 to a solid preclinical data package by June 2026, while progressing GoldenSite toward GMP readiness and partnering with ADC innovators.”

As part of the financing, Ana Maricevic joins Valanx’s Board of Directors, formally representing the Foundation Fournier-Majoie.